RecruitingPhase 2NCT05971758
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
Studying Cushing disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of California, Los Angeles
- Intervention
- Fimepinostat(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (1)
- Ronald Reagan Medical Center, Los Angeles, California, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05971758 on ClinicalTrials.govOther trials for Cushing disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT04569591DDAVP for Pituitary AdenomaNational Institute of Neurological Disorders and Stroke (NINDS)
- ENROLLING BY INVITATIONNANCT07108244Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's DiseaseUniversity Hospital, Basel, Switzerland
- RECRUITINGNCT07335315Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary TumorsMayo Clinic
- RECRUITINGNCT07463625Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors.Hospices Civils de Lyon
- ACTIVE NOT RECRUITINGNANCT04486859Postoperative Thrombosis Prevention in Patients With CDHuashan Hospital
- ACTIVE NOT RECRUITINGNCT03974789Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of HypercorticismsCentre Hospitalier Universitaire de Nīmes
- RECRUITINGNCT03831958Long-Term Follow-Up of Survivors of Pediatric Cushing DiseaseEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- RECRUITINGPHASE2NCT03774446Multicenter Study of Seliciclib (R-roscovitine) for Cushing DiseaseCedars-Sinai Medical Center